GSK chief backs affordable pricing in India

GlaxoSmithKline CEO Andrew Witty got on his soapbox in India to promote tiered drug pricing. "The setting of a price is a function of the affordability of the society in which we work," Witty said. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.